CADTH is pleased to announce the introduction of the Real-World Evidence (RWE) Guidance Working Group which reports to the Real-World Evidence Steering Committee. The objective of the Guidance Working Group is to develop clear and comprehensive guidance on the conduct, reporting, and appraising of RWE studies concerning the safety and effectiveness of health technologies for the purpose of regulatory approval and health technology assessment (HTA) in Canada.

Held in April or May every year since 2005, the CADTH Symposium has traditionally been a spring event.

Because of the COVID-19 pandemic, the 2020 CADTH Symposium was delayed until late fall and we continued with a fall date in 2021.

Now we are preparing for a return to the CADTH Symposium’s traditional time frame. Unfortunately, this means there will not be a 2022 CADTH Symposium. Instead, we are springing back to spring in 2023 with a hybrid Symposium that will provide both in-person and virtual attendance options.

CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation (PMDE) Network. Collaborators will bring additional expertise to the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.

The PMDE Program issued a request for proposals on March 15, 2022, for its Contractors. Proposals were reviewed by a multidisciplinary review panel that identified the following applicants to be PMDE Network Collaborators:

CADTH is pleased to announce the release of a new report entitled Building Toward a Potential Pan-Canadian Formulary: A Report From the Advisory Panel.

In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and managing a potential pan-Canadian prescription drug list (or formulary). CADTH convened a multidisciplinary advisory panel to undertake this work.

We are undertaking an innovative review for an antiviral treatment to address the recent monkeypox outbreaks.

Monkeypox has become a serious public health issue around the globe. According to WHO, the most recent case fatality ratio from monkeypox infection is about 3% to 6%. The causes of death have been documented in high-risk groups such as infants, children less than 10 years old, those who are pregnant, patients with complications, and those who are immunocompromised.

CADTH is pleased to announce the 4 successful Core Network Partners of its inaugural Post-Market Drug Evaluation (PMDE) Network. Core Network Partners will be the foundation of the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.  

The PMDE Program issued a request for proposals on February 1, 2022, for its Core Network Partners. Proposals were reviewed by a multidisciplinary review panel that identified the following 4 teams: 

June 1, 2022 – the pan-Canadian health technology assessment body, will host a national roundtable on models of care for post–COVID-19 condition on June 1, 2022.

Post–COVID-19 condition, or long COVID, is characterized by persistent or lingering symptoms that continue for weeks, months, or years after an initial COVID infection. Long COVID symptoms can include fatigue, difficulty breathing, memory issues, persistent cough, and depression.